Harmful and Beneficial Activities of Immunological Adjuvants

  • Duncan E. S. Stewart-Tull
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 42)

Abstract

There are no officially recognized regulations for the design and toxicity testing of adjuvants or adjuvant formulations; the former are also referred to as immunomodulators and immunopotentiators. At the “Immunological Adjuvants and Vaccines” meeting held in Greece in 1988, however, immunoadjuvant researchers discussed experimental toxicological tests that might be used to monitor new immunomodulators (1). The usefulness of these tests for the range of immunomodulators and adjuvant formulations was examined over a 2-yr period and subsequently, at the next NATO meeting in 1990, further recommendations were made (2). Although as yet, no final agreement has been reached and a variety of tests are still in use.

References

  1. 1.
    Stewart-Tull, D. E. S. (1989) Recommendations for the assessment of adjuvants (immuno-potentiators), in Immunological Adjuvants and Vaccines (Gregoriadis, G., Allison, A. C., and Poste, G., eds.), Plenum, New York, pp. 213–226.Google Scholar
  2. 2.
    Stewart-Tull, D. E. S. (1991) The assessment and use of adjuvants, in Vaccines (Gregoriadis, G., Allison, A. C., and Poste, G., eds.), Plenum, New York, pp. 85–92.CrossRefGoogle Scholar
  3. 3.
    Stewart-Tull, D. E. S. and Brown, F. (1993) First steps towards an international harmonization of veterinary biologicals. Vaccine 11, 692–695.PubMedCrossRefGoogle Scholar
  4. 4.
    Stewart-Tull, D. E. S. (1985) Immunopotentiating activity of peptidoglycan and surface polymers, in Immunology of the Bacterial Cell Envelope (Stewart-Tull, D. E. S. and Davies, M., eds.), Wiley, Chichester, pp. 47–89.Google Scholar
  5. 5.
    Robbins, J. (1980) in New Developments with Human and Veterinary Vaccines (Mizrahi, A., et al.) A R Liss, New York, pp. 393–394.Google Scholar
  6. 6.
    Vogel, F. R. and Powell, M. F. (1995) A compendium of vaccine adjuvants and excipients, in Vaccine Design. The subunit and adjuvant approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, pp. 141–227.Google Scholar
  7. 7.
    Campbell, J. B. (1995) Saponins, in The Theory and Practical Application of Adjuvants (Stewart-Tull, D. E. S., ed.), Wiley, Chichester, pp. 95–127.Google Scholar
  8. 8.
    British Standards Institution (1990) sEvaluation of medical devices for biological hazards Part 11. Method of test for haemolysis, British Standard 5736. British Standards Inst., 2, Park Street, London, W1A 2BS, England.Google Scholar
  9. 9.
    Wolff, S. M., Rubenstein, M., Mulholland, J. H., and Alling, D. W. (1965) Comparison of hematologic and febrile response to endotoxin in man. Blood 26, 190–201.PubMedGoogle Scholar
  10. 10.
    British Standards Institution (1990) Evaluation of medical devices for biological hazards, Part 5. Method of test for systemic toxicity; assessment of pyrogenicity in rabbits of extracts from medical devices, British Standard 5736, 5, British Standards Inst., 2, Park Street, London, W1A 2BS. England, pp. 1–3.Google Scholar
  11. 11.
    Wardlaw, A. C. and McCartney, A. C. (1985) Endotoxic activities of lipopolysac-charides, in Immunology of the bacterial cell envelope (Stewart-Tull, D. E. S. and Davies, M., eds.), Wiley, Chichester, pp. 203–238.Google Scholar
  12. 13.
    Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunolog. Meth. 65, 55–63.CrossRefGoogle Scholar
  13. 14.
    Vega, M. V., Maheswaran, S. K., Leininger, J. R., and Ames, T. R. (1987) Adaptation of a colorimetric microtitration assay for quantifying Pasteurella haemolytica A1 leucotoxin and anti-leukotoxin. Am. J. Vet. Res. 48, 1559–1564.PubMedGoogle Scholar
  14. 15.
    Craig, F. F., Dalgleish, R., Sutherland, A. D., Parton, R., Coote, J. G., Gibbs H. A., and Freer, J. H. (1990) A colourimetric, microplate assay for the leucotoxin of Pasteurella haemolytica. Vet. Microbiol. 22, 309–317.PubMedCrossRefGoogle Scholar
  15. 16.
    Ferrari, M., Fornasiero, M. C., and Isetta, A. M. (1990) MTT colorimetric assay for testing macrophage cytotoxicity activity in vitro. J. Immunolog. Meth. 131, 165–172.CrossRefGoogle Scholar
  16. 17.
    Borefreund, E., Babich, H., and Martin-Alguacil, N. (1988) Comparisons of two in vitro cytotoxicity assays-the neutral red (NR) and tetrazolium MTT tests. Toxicol. in Vitro 2, 1–6.CrossRefGoogle Scholar
  17. 18.
    British Standards Institution (1983) Evaluation of medical devices for biological hazards. Part 7. Method of test for skin irritation of extracts from medical devices. British Standard 5736, 7. British Standards Inst., 2, Park Street, London, W1A 2BS, England, pp. 1–3.Google Scholar
  18. 19.
    Kensil, C. R., Patel, U., Lennick, M., and Marciani, D. (1991) Structure and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146, 431–437.PubMedGoogle Scholar
  19. 20.
    British Standards Institution (1983) Evaluation of medical devices for biological hazards. Part 3. Method of test for systemic toxicity; assessment of acute toxicity of extracts from medical devices. British Standard 5736, 3, British Standards Inst., 2, Park Street, London, W1A 2BS, England, pp. 1–2.Google Scholar
  20. 21.
    Christodoulides, M., Sidey, F. M., Parton, R., and Stewart-Tull, D. E. S. (1987) Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure. Vaccine 5, 199–207.PubMedCrossRefGoogle Scholar
  21. 22.
    World Health Organization (1976) Immunological adjuvants. Tech. Rep. Ser. 595, 3.Google Scholar
  22. 23.
    Stewart-Tull, D. E. S. and Jones, A. C. (1992) Adjuvants should not induce allergic reactions to protein antigens. FEMS Lett. 100, 489–496.Google Scholar
  23. 24.
    Stewart-Tull, D. E. S. (1995) Freund-type mineral oil adjuvant emulsions, in The Theory and Practical Application of Adjuvants (Stewart-Tull, D. E. S., ed.), Wiley, Chichester, pp. 1–19.Google Scholar
  24. 25.
    Davenport, F. M. (1968) Seventeen years experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 26, 288–292.PubMedGoogle Scholar
  25. 26.
    Stewart-Tull, D. E. S., Shimono T., Kotani S., and Knights, B. A. (1976) Immunosuppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons. Int. Arch. Allergy Appl. Immunol. 52, 118–128.CrossRefGoogle Scholar
  26. 27.
    Pearson, C. M. (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvant. Proc. Soc. Exp. Biol. Med. 91, 95–101.PubMedGoogle Scholar
  27. 28.
    European Community (1989) The rules governing medicinal products in the European Community, Vol. III, Guidelines on the quality, safety, and efficacy of medicinal products for human use. CB-55-89-293-EN-C.Google Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Duncan E. S. Stewart-Tull
    • 1
  1. 1.Division of Infection and Immunity, Institute for Biomedical and Life SciencesUniversity of GlasgowUK

Personalised recommendations